TPP+-containing mitochondria-targeting agents (e.g., Mito-metformin) inhibit pancreatic cancer cell proliferation via downregulation of the Akt/FOXO3/FOXM1 signaling axis in pancreatic cancer cells. The gene discussed is FOXO3; the disease is pancreatic neoplasm.